This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

GABA BTU Stock Overview

A pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. More details

GABA BTU fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Shares are highly illiquid

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Gabather AB (publ) Competitors

Ziccum

OM:ZICC

SEK 7.4m

ODI Pharma

NGM:ODI

SEK 38.5m

DanCann Pharma

NGM:DANCAN

DKK 6.7m

Newbury Pharmaceuticals

OM:NEWBRY

SEK 79.1m

Price History & Performance

Summary of share price highs, lows and changes for Gabather
Historical stock prices
Current Share Price	SEK 1.40
52 Week High	SEK 1.70
52 Week Low	SEK 1.02
Beta	0.27
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-6.67%

Recent updates

Shareholder Returns

	GABA BTU	SE Pharmaceuticals	SE Market
7D	7.7%	-9.1%	-1.5%
1Y	n/a	-3.8%	3.3%

Return vs Industry: Insufficient data to determine how GABA BTU performed against the Swedish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how GABA BTU performed against the Swedish Market.

Price Volatility

Is GABA BTU's price volatile compared to industry and market?
GABA BTU volatility
GABA BTU Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.0%
10% most volatile stocks in SE Market	13.1%
10% least volatile stocks in SE Market	3.4%

Stable Share Price: GABA BTU has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine GABA BTU's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	3	Michael-Robin Witt	www.gabather.com

Gabather AB (publ), a pharmaceutical company, researches and develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics; anti-depressants and anxiolytics; analgesics; and cognition-enhancing treatments, including Alzheimer’s disease. The company develops GT-002 for the treatment of schizophrenia, major depressive disorder, orphan drug, and alzheimer´s disease.

Gabather AB (publ) Fundamentals Summary

How do Gabather's earnings and revenue compare to its market cap?
GABA BTU fundamental statistics
Market cap	SEK 16.37m
Earnings (TTM)	-SEK 10.68m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.5x

P/E Ratio

Is GABA BTU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GABA BTU income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 10.68m
Earnings	-SEK 10.68m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.45
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did GABA BTU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/02 12:34
End of Day Share Price	2024/09/02 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gabather AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Gabather OM:GABA BTU Stock Report